Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.
Altrichter S, Giménez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, Brooks L, Ho CN, Jain P, Lukka PB, Rodriguez-Suárez E, Walton C, Datto CJ; ARROYO Study Investigators. Altrichter S, et al. Br J Dermatol. 2024 Feb 17:ljae067. doi: 10.1093/bjd/ljae067. Online ahead of print. Br J Dermatol. 2024. PMID: 38367194
EUSCAP: A Euromelanoma project to investigate skin cancer risk factors in Europe.
Wunderlich K, Suppa M, Lipski J, Deworme V, Wambreuse A, Njimi H, White J, Gaide O; Euromelanoma Working Group; Gandini S, Del Marmol V. Wunderlich K, et al. J Eur Acad Dermatol Venereol. 2023 Dec 8. doi: 10.1111/jdv.19710. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 38069540 No abstract available.
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Stratigos A, Trakatelli M, Puig L; EADV Burden of Skin Diseases Project Team. Richard MA, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37 Suppl 7:17-24. doi: 10.1111/jdv.18916. J Eur Acad Dermatol Venereol. 2023. PMID: 37806003
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
32 results